Last reviewed · How we verify

Fluoropyrimidine-based Chemotherapy — Competitive Intelligence Brief

Fluoropyrimidine-based Chemotherapy (Fluoropyrimidine-based Chemotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy. Area: Oncology.

phase 3 Antimetabolite chemotherapy Thymidylate synthase; DNA/RNA incorporation Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fluoropyrimidine-based Chemotherapy (Fluoropyrimidine-based Chemotherapy) — Hoffmann-La Roche. Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fluoropyrimidine-based Chemotherapy TARGET Fluoropyrimidine-based Chemotherapy Hoffmann-La Roche phase 3 Antimetabolite chemotherapy Thymidylate synthase; DNA/RNA incorporation
Chemotherapy（pemetrexed/gemcitabine） Chemotherapy（pemetrexed/gemcitabine） Shanghai Pulmonary Hospital, Shanghai, China phase 3 Antimetabolite chemotherapy combination Thymidylate synthase, dihydrofolate reductase (pemetrexed); ribonucleotide reductase, DNA polymerase (gemcitabine)
Capecitabine or gemcitabine Capecitabine or gemcitabine Centre Hospitalier Universitaire Dijon phase 3 Antimetabolite chemotherapy agents Thymidylate synthase (capecitabine); Ribonucleotide reductase and DNA polymerase (gemcitabine)
UFT adjuvant chemotherapy UFT adjuvant chemotherapy Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan phase 3 Antimetabolite chemotherapy Thymidylate synthase
ATRA plus 6-MP and MTX ATRA plus 6-MP and MTX Wyeth is now a wholly owned subsidiary of Pfizer phase 3 Retinoid plus antimetabolite chemotherapy combination PML-RARA fusion protein (ATRA); DHFR and TPMT (MTX and 6-MP)
Chemotherapy,Gemcitabine based regimen Chemotherapy,Gemcitabine based regimen Eye & ENT Hospital of Fudan University phase 3 Nucleoside analog; antimetabolite chemotherapy Ribonucleotide reductase; DNA polymerase
Chemotherapy, gemcitabine Chemotherapy, gemcitabine University of Erlangen-Nürnberg Medical School phase 3 Nucleoside analog; antimetabolite chemotherapy Ribonucleotide reductase; DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy class)

  1. Hoffmann-La Roche · 1 drug in this class
  2. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  3. Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluoropyrimidine-based Chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoropyrimidine-based-chemotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: